LOCF indicates last observation carried forward.
The 3 graphs on the left show the treatment effect of endovascular therapy, expressed as the common odds ratio (OR) for improved functional outcome (solid blue line) and its 95% CI (dashed blue lines) expressed as a function of onset-to-randomization time (A), age (C), and baseline National Institutes of Health Stroke Scale (NIHSS) score (E). The treatment effect did not change with any of these baseline variables. The 3 graphs on the right show the probability and 95% CI of functional independence at 90 days, separately for patients in the endovascular treatment arm (orange lines and shading) and the medical control arm (blue lines and shading). The probability of functional independence was not associated with onset-to-randomization time (B), but declined in both treatment arms with older age (D) and higher NIHSS score (F). Graphical results are for a hypothetical patient for whom covariates are fixed at the DEFUSE 3 population mean (age 69 years, NIHSS score of 16, and serum glucose of 140 mg/dL). The analysis for time from onset-to-randomization are based on the subset of patients who had a known time of stroke onset (n = 66). The other analyses are based on all patients randomized in the DEFUSE 3 trial (n = 182). mRS indicates modified Rankin Scale.
This figure shows the 90-day mRS distributions stratified by location of the arterial occlusion (A) and type of imaging modality used to select patients with salvageable tissue (B). A, Endovascular therapy was associated with improved outcomes in patients with middle cerebral artery (MCA) (odds ratio for functional independence 6.0; 95% CI, 2.0-17.9) and internal carotid artery (ICA) occlusions 10.6 (95% CI, 2.2-49.8; P for lesion location × treatment interaction = .54). B, Endovascular therapy was associated with improved outcomes in patients selected with magnetic resonance imaging (MRI) (odds ratio, 11.9; 95% CI, 2.2-63.4) and patients selected with computed tomography (CT) (odds ratio, 6.1; 95% CI, 2.2-17.1; P for imaging modality × treatment interaction = .49). Reported odds ratios are adjusted for age, National Institutes of Health Stroke Scale score, and serum glucose level.
eFigure 1. Probability of functional outcome as a function of onset to randomization time
eFigure 2. Probability of functional outcome as a function of age
eFigure 3. Probability of functional outcome as a function of baseline NIHSS
eFigure 4. Relationship between onset-to-randomization and onset-to-femoral puncture time
Data Sharing Statement
Customize your JAMA Network experience by selecting one or more topics from the list below.
Lansberg MG, Mlynash M, Hamilton S, et al. Association of Thrombectomy With Stroke Outcomes Among Patient Subgroups: Secondary Analyses of the DEFUSE 3 Randomized Clinical Trial. JAMA Neurol. 2019;76(4):447–453. doi:10.1001/jamaneurol.2018.4587
Is the benefit of endovascular stroke therapy in the extended (6 to 16 hours) time window universal or limited to subgroups?
In this secondary analysis of a randomized clinical trial, endovascular therapy resulted in in better functional outcome among a broad patient population. Treatment effect was not significantly modified by age (range, 23-90 years), symptom severity (National Institutes of Health Stroke Scale range, 6-38), time to randomization (range, 6-16 hours), arterial occlusive lesion location (internal carotid artery or middle cerebral artery), or imaging modality (computed tomography or magnetic resonance imaging).
Endovascular therapy should not be withheld because of old age, mild symptoms, or late presentation in patients with large-vessel strokes and salvageable tissue on computed tomography or magnetic resonance imaging.
The DEFUSE 3 randomized clinical trial previously demonstrated benefit of endovascular thrombectomy for acute ischemic stroke in the 6- to 16-hour time window. For treatment recommendations, it is important to know if the treatment benefit was universal.
To determine the outcomes among patients who may have a reduced effect of thrombectomy, including those who are older, have milder symptoms, or present late.
Design, Setting, and Participants
DEFUSE 3 was a randomized, open-label, blinded end point trial conducted from May 2016 to May 2017. This multicenter study included 38 sites in the United States. Of 296 patients who were enrolled in DEFUSE 3, 182 patients met all inclusion criteria and were randomized and included in the intention-to-treat analysis, which was conducted in August 2017. These patients had acute ischemic strokes due to an occlusion of the internal carotid artery or middle cerebral artery and evidence of salvageable tissue on perfusion computed tomography or magnetic resonance imaging. The study was stopped early for efficacy.
Endovascular thrombectomy plus medical management vs medical management alone.
Main Outcomes and Measures
Functional outcome at day 90, assessed on the modified Rankin Scale. Multivariate ordinal logistic regression was used to calculate the adjusted proportional association between endovascular treatment and clinical outcome (shift in the distribution of modified Rankin Scale scores expressed as a common odds ratio) among patients of different ages, baseline stroke severities, onset-to-treatment times, locations of the arterial occlusion, and imaging modalities used to document the presence of salvageable tissue (computed tomography vs magnetic resonance imaging).
This study included 182 patients (median [interquartile range] age, 70 [59-80] years; median [interquartile range] National Institutes of Health Stroke Scale score, 16 [11-21], and 92 women [51%]). In the overall cohort, independent predictors of better functional outcome were younger age, lower baseline National Institutes of Health Stroke Scale score, and lower serum glucose level. The common odds ratio for improved functional outcome with endovascular therapy, adjusted for these variables, was 3.1 (95% CI, 1.8-5.4). There was no significant interaction between this treatment effect and age (P = .93), National Institutes of Health Stroke Scale score (P = .87), time to randomization (P = .56), imaging modality (P = .49), or location of the arterial occlusion (P = .54).
Conclusions and Relevance
Endovascular thrombectomy, initiated up to 16 hours after last known well time in patients with salvageable tissue on perfusion imaging, benefits patients with a broad range of clinical features. Owing to the small sample size of this study, a pooled analysis of late time window endovascular stroke trials is needed to confirm these results.
ClinicalTrials.gov identifier: NCT02586415
Multiple randomized clinical trials have demonstrated that endovascular thrombectomy is effective for the treatment of ischemic stroke if treatment is initiated within 6 hours of symptom onset. Recently, 2 randomized clinical trials, DAWN1 (DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo) and DEFUSE 32 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke), demonstrated that the time window for thrombectomy can be substantially extended in patients selected on the basis of advanced neuroimaging techniques. The trials led to a revision of the American Heart Association/American Stroke Association Guidelines for stroke therapy: thrombectomy up to 16 hours after onset received a level 1A recommendation and thrombectomy in the 16- to 24-hour time window received a level 2B recommendation.3
In DEFUSE 3,2 patients who were likely to have salvageable ischemic brain tissue identified on perfusion imaging were randomized to receive endovascular therapy vs standard medical therapy 6 hours to 16 hours after they were last known to have been well. Compared with the medical therapy group, patients in the endovascular therapy group had a favorable shift in the distribution of functional outcomes at 90 days (P < .001), a higher percentage of functional independence (44.6% vs 16.7%, P < .001), and a lower 90-day mortality rate (14% vs 26%, P = .05). The rate of symptomatic intracranial hemorrhage was similar between the 2 groups (7% and 4%, respectively, P = .75).2
As these findings are translated into clinical practice, a fundamental question is whether the benefits of thrombectomy apply to diverse patient subgroups, including very elderly persons, patients with mild symptoms, and patients who present toward the end of the 16-hour time window. Furthermore, there is uncertainty regarding whether magnetic resonance imaging (MRI) or computed tomography (CT) perfusion is the optimal imaging modality for evaluation of late-window patients and whether both patients with middle cerebral artery (MCA) and internal carotid artery (ICA) occlusion have similar treatment benefits. The goal of this study is to examine if the benefit of thrombectomy is uniform among diverse patient subgroups.
The DEFUSE 3 study was a prospective open-label randomized clinical trial of endovascular therapy plus medical management vs medical management alone for patients presenting in the 6- to 16-hour time window with imaging evidence on CT or MRI of a large vessel occlusion and salvageable tissue. The study was approved by the StrokeNet Central institutional review board at the University of Cincinnati. All patients or their proxy signed informed consent. Details of the study protocol have been published previously4 and are available in Supplement 1.
Here we report the results of prespecified analyses that assess the association of endovascular therapy in subgroups based on site of arterial occlusive lesion (ICA vs MCA) and imaging modality used for patient selection (MRI vs CT). We also report post hoc analyses investigating the association of endovascular therapy as a function of onset-to-randomization time, baseline National Institutes of Health Stroke Scale (NIHSS) score, and age. All patients who were randomized in the DEFUSE 3 study were included in the analyses (N = 182), except for the analysis regarding onset-to-randomization time, which was limited to patients for whom the exact time of symptom onset was known (n = 66) (Figure 1). Location of the arterial occlusive lesion (ICA vs MCA) was determined by the DEFUSE 3 radiology core laboratory, based on a review of the baseline CT or MRI angiogram. The imaging modality (CT or MRI) used to qualify a patient for the DEFUSE 3 study was defined as the imaging modality that demonstrated presence of a substantial volume of salvageable tissue (an ischemic core less than 70 mL, a relative volume of potentially reversible ischemia of 80% or more, and an absolute volume of potentially reversible ischemia of 15 mL or more).
The primary outcome for the analyses was 90-day functional outcome assessed on the ordinal modified Rankin Scale (mRS). The secondary outcome was the percentage of patients who were functionally independent, defined as an mRS score of 2 or less at day 90. For 3 patients who were lost to follow-up at day 90, the mRS score at day 30 was used as their primary outcome under the last observation carried forward principle.
We first constructed proportional odds models to identify independent predictors of outcome. Functional outcome at day 90 was the dependent variable in each model. Independent variables tested in univariable analyses included those that have previously been shown to affect outcome (treatment assignment, time to randomization, age, NIHSS score, sex, glucose, systolic blood pressure, lesion volume). Variables significant at α < .10 in univariate analyses were entered into a multivariable model and were retained in the multivariable model if they were significant at α < .05. This served as our base model for subsequent analyses of treatment effect modification. To determine how the treatment effect changes with age, NIHSS score, time, arterial occlusive lesion, and imaging modality, we created 5 separate models; these were created by adding the variable of interest and its interaction term with treatment as independent variables to the base model. Treatment effects were expressed as adjusted common odds ratios (ORs) for improved functional outcome with endovascular therapy. When the test for proportionality of the ORs was rejected, we used logistic regression models with functional independence (mRS 0-2) as the dependent variable instead of ordinal logistic regression and expressed results as adjusted ORs for functional independence with endovascular therapy. All tests were 2 sided, and analyses were performed with SAS version 9.4 (SAS Institute Inc).
DEFUSE 3 randomized 182 patients, 92 of whom were assigned to endovascular therapy. All 182 patients were included in the analyses for this study. Univariable and multivariable predictors of functional outcome on the full range of mRS scores are presented in the Table. Significant covariates of better functional outcome in multivariable analysis were younger age, lower baseline NIHSS score, and lower serum glucose level. All analyses reported below were adjusted for these covariates.
The common OR for improved functional outcome with endovascular therapy, adjusted for age, NIHSS score, and serum glucose was 3.1 (95% CI, 1.8-5.4). There was no interaction between treatment and (A) time to randomization (common OR for improved functional outcome with each hour of longer time to randomization, 0.84; 95% CI, 0.67-1.06 in medical group vs 0.93; 95% CI, 0.73-1.17 in endovascular group; P for interaction = .56; range 6-16 hours), (B) age (common OR for improved functional outcome with each year of older age, 0.95; 95% CI, 0.92-0.98 in medical group vs 0.95; 95% CI, 0.92-0.98 in endovascular group; P for interaction = .93; age range, 23-90 years), or (C) baseline stroke severity at time of randomization (common OR for improved functional outcome with each point of higher NIHSS score, 0.88; 95% CI, 0.82-0.94 in medical group vs 0.88; 95% CI, 0.83-0.94 in endovascular group; P for interaction = .87; NIHSS score range 6-38) (Figure 2). The probability of being functionally independent (mRS 0-2) at day 90, the secondary study end point, declined with older age and higher NIHSS score in the endovascular and medical treatment arms. A similar pattern of declining probabilities in both treatment arms was observed for other dichotomous end points of the mRS (eFigures 1 to 3 in Supplement 2).
Logistic regression, with functional independence (mRS 0-2) as the dependent variable, yielded an adjusted OR for endovascular therapy of 10.6 (95% CI, 2.2-49.8) among patients with ICA occlusions and 6.0 (95% CI, 2.0-17.9) for patients with MCA occlusions (P for lesion location × treatment interaction = .54). Analysis stratified by imaging modality showed an adjusted OR of 11.9 (95% CI, 2.2-63.4) for patients selected with MRI and 6.1 (95% CI, 2.2-17.1) for patients selected with CT (P for imaging modality × treatment interaction = .49) (Figure 3).
Time from onset to randomization was strongly correlated with time from onset to femoral puncture (R2 = 0.99; β = .98; P < .001) with femoral puncture occurring on average 31 minutes after randomization. (eFigure 4 in Supplement 2). Median (interquartile range [IQR]) times from hospital arrival to randomization were similar for CT (1:20 [0:51-2:07]) and MR (1:21 [0:50-1:49], P = .42), but the CT group had longer onset-to-randomization times (11:03 [9:16-12:53]) than MR (10:33 [8:08-11:28], P = .03) and longer hospital arrival-to-femoral puncture times (2:00 [1:21-2:48]) than MR (1:28 [1:14-2:06]; P = .02). Among patients with witnessed strokes, the CT group also had longer onset-to-randomization times (median [IQR], 10:06 [8:25-13:18]) than MR (median [IQR], 8:33 [7:30-10:46]; P = .01) The proportion of patients selected by MRI did not differ between patients who were transferred to the study site from an outside hospital (35 of 121 [29%]) and patients who were admitted directly to the study site (14 of 61 [23%], P = .48).
This study demonstrates worse functional outcomes in patients who are older, have more severe symptoms on presentation (higher NIHSS score), and have higher serum glucose, but does not show modification of the treatment effect according to these or other baseline variables. Specifically, the proportional benefit of endovascular thrombectomy is uniform across patients with a wide range in age, symptom severity, and time from stroke onset-to-randomization and also does not differ according to the location of the arterial occlusive lesion and the imaging modality used for patient selection. While the proportional benefit (OR for improved functional outcome) is uniform, differences do exist in the absolute treatment benefit (the increase in the probability of achieving a desired functional outcome) across patients.
Our results indicate that advanced age, up to 90 years, should not be considered a contraindication to thrombectomy, provided that the patient is fully independent prior to stroke onset. Although age did not modify the treatment effect, it was a strong independent predictor of 90-day disability, which is consistent with prior studies of both tissue plasminogen activator and endovascular therapy.5,6 In DEFUSE 3, only about 20% of very elderly persons achieved functional independence following thrombectomy; however, the rate in the medical control group was nearly 0. As patients older than 90 years were excluded from DEFUSE 3, our results may not apply to nonagenarians, and because DEFUSE 3 required patients to be nondisabled prior to stoke onset, our results may also not apply to elderly patients with preexisting disability.
Consistent with prior studies of thrombolytic and endovascular therapy, baseline stroke severity was a powerful independent predictor of clinical outcome1,6 but did not modify treatment effect as demonstrated by a uniform proportional benefit of endovascular therapy for patients with NIHSS scores ranging from 6 to 38. However, this uniform proportional benefit does not imply that there also is a uniform absolute benefit. For example, patients with low NIHSS scores experienced a substantial absolute benefit in their chance of achieving functional independence but had no reduction in mortality, whereas patients with high NIHSS scores experienced a very limited benefit in functional independence but did have a reduction in mortality and severe disability (eFigure 3 in Supplement 2) A similar pattern of differences in absolute benefits with endovascular treatment was seen for patients of different ages (eFigure 2 in Supplement 2).
Although good outcome rates were overall higher in patients with MCA occlusions, both patients with occlusions of the proximal segment of the MCA and patients with ICA occlusions benefitted from late window thrombectomy and we did not demonstrate a difference in treatment effects between groups. Similarly, patients who were selected based on CT perfusion imaging and those selected based on MRI diffusion and perfusion imaging both benefitted from endovascular therapy. These results indicate that both CT and MRI perfusion can be used for patient selection and that patients with ICA and MCA occlusions are suitable candidates for late-window endovascular therapy. A limitation of this study is that the overall sample was relatively small and we therefore had limited power to demonstrate significant differences in treatment effects between these subgroups. We were also unable to address M2 MCA segment or basilar artery occlusions as these patients were excluded from DEFUSE 3.
Among patients with known time of stroke onset, there was no attenuation of the treatment effect with increasing time between stroke onset and randomization. The lack of an association between time and treatment effect is likely explained by the study’s imaging selection criteria. All patients in DEFUSE 3 were required to have a substantial volume of salvageable tissue (ie, a target mismatch on CT or MRI perfusion imaging). Given that DEFUSE 3 was a late window trial, this requirement limited the population to patients with favorable collaterals who have slow growth of their ischemic cores. This is illustrated by the fact that the majority of patients in DEFUSE 3 had core volumes of 10 mL or less even though the median time between symptom onset and brain imaging was longer than 10 hours. Assuming that core growth is linear, this translates into a mean early core growth rate of 1 mL per hour. At these low rates, treatment delays likely do not have a substantial impact on the treatment effect. However, these findings should not be used as a justification to treat late-presenting patients with less urgency than early-presenting patients. Since the ischemic core grows with time (albeit slowly in some instances) and the penumbra thus shrinks with time,7 a patient’s chance of having a substantial volume of salvageable tissue that fulfills criteria for late-window endovascular therapy decreases if imaging is delayed.
The lack of an association between time to treatment and treatment effect in DEFUSE 3 is consistent with our findings from the DEFUSE 28 and CRISP9 studies. These studies showed no attenuation of the association of endovascular reperfusion with longer onset-to-treatment times among patients with the target mismatch profile.10,11 However, our results are in contrast with the pooled analyses of prior endovascular and thrombolytic therapy trials, which have shown an attenuation of the treatment effect with longer onset-to-treatment times.12,13 This discrepancy could be explained by a much higher proportion of patients with rapidly expanding ischemic cores in prior trials, as these trials did not require evidence of a substantial volume of salvageable tissue for inclusion. Limited power to detect an association of time in the DEFUSE 3 cohort may also have been a factor.
While we did not detect differences in treatment effects between patient subgroups, it is possible that small differences went undetected owing to the small sample size of this study. These results therefore warrant validation in other trials of late-window endovascular therapy.
Endovascular therapy in the 6- to 16-hour time window among patients with evidence of salvageable tissue on brain perfusion imaging is beneficial in a broad patient population, including patients who range in age from 23 to 90 years, who have mild or severe symptoms, who are treated between 6 and 16 hours after their last known well time, who are selected by CT or MRI, and who have strokes due to either ICA or MCA occlusions.
Corresponding Author: Maarten G. Lansberg, MD, PhD, Stanford Stroke Center, 780 Welch Rd, Ste 350, Palo Alto, CA 94304-5778 (email@example.com).
Accepted for Publication: October 19, 2018.
Published Online: January 28, 2019. doi:10.1001/jamaneurol.2018.4587
Author Contributions: Dr Lansberg had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Lansberg, Hamilton, Lavori, Heit, Albers.
Acquisition, analysis, or interpretation of data: Lansberg, Mlynash, Hamilton, Yeatts, Christensen, Kemp, Ortega-Gutierrez, Broderick, Heit, Marks, Albers.
Drafting of the manuscript: Lansberg, Hamilton, Albers.
Critical revision of the manuscript for important intellectual content: Mlynash, Hamilton, Yeatts, Christensen, Kemp, Lavori, Ortega-Gutierrez, Broderick, Heit, Marks, Albers.
Statistical analysis: Lansberg, Mlynash, Hamilton, Yeatts, Lavori.
Obtained funding: Lansberg, Broderick, Albers.
Administrative, technical, or material support: Lansberg, Christensen, Kemp, Ortega-Gutierrez, Broderick.
Supervision: Lansberg, Kemp, Broderick, Albers.
Conflict of Interest Disclosures: Dr Yeatts received consulting fees from Genentech for her role on the PRISMS Trial Steering Committee, and her institution is contracted to receive fees from BARD Medical for her Data and Safety Monitoring Board services. Dr Christensen received consulting fees and is shareholder of iSchemaView, which produces the software used in this trial for postprocessing of computed tomography and magnetic resonance imaging perfusion studies. Dr Ortega-Gutierrez received consulting fees from Medtronic and Stryker Neurovascular. Dr Broderick received consulting fees from Genentech and Pfizer. Dr Marks is a shareholder in ThrombX Medical. Dr Albers received consulting fees and is a shareholder of iSchemaView, which produces the software used in this trial for postprocessing of computed tomography and magnetic resonance imaging perfusion studies. Dr Albers holds a patent related to iSchemaView. No other disclosures were reported.
Funding/Support: The study was funded by grants from the National Institute for Neurological Disorders and Stroke (U10NS086487 and U01NS092076, Dr Albers).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: The DEFUSE 3 Group members are Santiago Ortega-Gutierrez, MD, University of Iowa Hospitals & Clinics; Enrique Leira, MD, University of Iowa Hospitals & Clinics; Ryan McTaggart, MD, Rhode Island Hospital; Shadi Yaghi, MD, Rhode Island Hospital; Michel Torbey, MD, Ohio State University Wexner Medical Center; Ciarán J. Powers, MD, Ohio State University Wexner Medical Center; May Kim-Tenser, MD, Keck Hospital of University of Southern California; Matthew Tenser, MD, Keck Hospital of University of Southern California; Maarten Lansberg, MD, Stanford University Medical Center; Michael Marks, MD, Stanford University Medical Center; Thabele Leslie-Mazwi, MD, Massachusetts General Hospital; Robert Hurst, MD, Hospital of the University of Pennsylvania; Scott Kasner, MD, Hospital of the University of Pennsylvania; Amrou Sarraj, MD, Memorial Hermann Texas Medical Center; Gary Spiegel, MD, Memorial Hermann Texas Medical Center; Sameer A. Ansari, MD, Northwestern University, Feinberg School of Medicine; Shyam Prabhakaran, MD, Northwestern University, Feinberg School of Medicine; Dorothea Altschul, MD, Valley Hospital; Adam de Havenon, MD, University of Utah Healthcare; Min Park, MD, University of Utah Healthcare; Johanna Fifi, MD, Mount Sinai Hospital; Stanley Tuhrim, MD, Mount Sinai Hospital; Robert Hoesch, MD, Intermountain Medical Center; Duane Blatter, MD, Intermountain Medical Center; Yasha Kayan, MD, Abbott Northwestern Hospital; Mark Young, MD, Abbott Northwestern Hospital; Ray Stephens, MD, John Muir Medical Center; Ira Finch, MD, John Muir Medical Center; Arash Afshinnik, MD, University of California San Francisco, Fresno; Robert Ryan, MD, University of California San Francisco, Fresno; Neeraj Chaudhary, MD, University of Michigan Medical Center; Devin Brown, MD, University of Michigan Medical Center; Steven Feske, MD, Brigham and Women’s Hospital; Ali Aziz-Sultan, MD, Brigham and Women’s Hospital; Wade Smith, MD, University of California San Francisco Medical Center; Daniel Cooke, MD, University of California San Francisco Medical Center; Steven Warach, MD, University Medical Center Brackenridge/Dell Medical School; Jefferson Miley, MD, University Medical Center Brackenridge/Dell Medical School; Azam Ahmed, MD, University of Wisconsin, Madison; Edward Bradbury, MD; University of Wisconsin, Madison; Hormozd Bozorgchami, MD, Oregon Health & Science University; Ryan Priest, MD, Oregon Health & Science University; Toby Gropen, MD, University of Alabama, Birmingham; Mark Harrigan, MD, University of Alabama, Birmingham; Mary Kalafut, MD, Scripps Memorial Hospital La Jolla; Giuseppe Ammirati, MD, Scripps Memorial Hospital La Jolla; Brett Meyer, MD, University of California San Diego Medical Center–Hillcrest Hospital; Alexander Khalessi, MD, University of California San Diego Medical Center–Hillcrest Hospital; Gottfried Schlaug, MD, Beth Israel Deaconess Medical Center; Souvik Sen, MD. Palmetto Health University of South Carolina; Roham Moftakhar, MD, Palmetto Health University of South Carolina; Christopher Streib, MD, Hennepin County Medical Center; Bharathi D. Jagadeesan, MD, Hennepin County Medical Center; Gabor Toth, MD, Cleveland Clinic; Ken Uchino, MD, Cleveland Clinic; Amie Hsia, MD, MedStar Washington Hospital Center; Ai-Hsi Liu, MD, MedStar Washington Hospital Center; Bharathi D. Jagadeesan, MD, University of Minnesota Medical Center Fairview; Christopher Streib, MD, University of Minnesota Medical Center Fairview; Achala Vagal, MD, University of Cincinnati Medical Center; Andrew J. Ringer, MD, University of Cincinnati Medical Center; Joshua Z. Willey, MD, NewYork-Presbyterian Columbia University Medical Center; Philip M. Meyers, MD, NewYork-Presbyterian Columbia University Medical Center; Osama O. Zaidat, MD, Mercy Health St Vincent Hospital and Medical Center; Michael Froehler, MD, Vanderbilt University Hospital; Dana Leifer, MD, NewYork-Presbyterian Weill Cornell Medical Center; Athos Patsalides, MD, NewYork-Presbyterian Weill Cornell Medical Center; Ted Lowenkopf, MD, Providence Health & Services; Vivek Deshmukh, MD, Providence Health & Services; David Tirschwell, MD, Harborview Medical Center; Danial Hallam, MD, Harborview Medical Center.
Data Sharing Statement: See Supplement 3.
Create a personal account or sign in to: